Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells
OwnerIain MCGILL, Christopher James SHARPEinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of adoptive cell therapy (ACT), particularly to a method for conditioning a subject for treatment with a medicament comprising regulatory T cells (Tregs), the method comprising administering a low dose of anti-thymocyte globulin (ATG) to the subject about 8 weeks or less before administration of the medicament.
Claims30
A method for conditioning a subject for treatment with a medicament comprising regulatory T cells (Tregs), the method comprising administering a low dose of anti-thymocyte globulin (ATG) to the subject about 8 weeks or less before administration of the medicament.
A method of immunomodulation of a subject in need thereof comprising the steps of:
- (a) administering a low dose of anti-thymocyte globulin (ATG) to the subject;
- and
- (b) administering a medicament comprising regulatory T cells (Tregs) to the subject,
- wherein step (a) occurs about 8 weeks or less before step (b).
A low dose of anti-thymocyte globulin (ATG) for use in conditioning a subject for treatment with a medicament comprising regulatory T cells (Tregs), wherein said ATG is for administration about 8 weeks or less before administration of the medicament.
A low dose of anti-thymocyte globulin (ATG) for use in immunomodulation of a subject in need thereof, wherein said immunomodulation comprises administration of a medicament comprising regulatory T cells (Tregs) to the subject and wherein said low dose of ATG is for administration about 8 weeks or less before administration of said medicament.
A combination therapy or product comprising a low dose of anti-thymocyte globulin (ATG) and a medicament comprising regulatory T cells (Tregs), wherein the components of the combination therapy or product are for separate and sequential use in immunomodulation of a subject, wherein said ATG is for administration about 8 weeks or less before administration of the medicament.
A kit comprising:
- (i) anti-thymocyte globulin (ATG);
- and
- (ii) a medicament comprising regulatory T cells (Tregs),
- for separate and sequential use in the immunomodulation of a subject, wherein said ATG is for administration at a low dose about 8 weeks or less before administration of the medicament.
Dependencies are inferred from the claim text.